Literature DB >> 8695564

Systemic effects of screening for retinopathy of prematurity.

D E Laws1, C Morton, M Weindling, D Clark.   

Abstract

AIMS: To detect systemic complications of screening for retinopathy of prematurity (ROP), paying particular attention to the physical examination.
METHODS: Oxygen saturation, pulse rate, and blood pressure were monitored before, during, and after 110 ROP screening examinations.
RESULTS: Following topical mydriatics diastolic blood pressure was elevated by a mean of 6 (SD 7.2) mm Hg. Immediately after the examination there was a further rise in both systolic and diastolic pressure of 4.3 (14.5) mm Hg and 3.3 (11.6) mm Hg, respectively. Oxygen saturation and pulse rate remained stable during the control period and administration of eyedrops. Saturation fell by a median of 3% (95% confidence interval plus or minus 1.2%) after the examination while there was rise in pulse rate of 7 (SD 23.1) beats per minute. This change in pulse rate was not observed in infants on concurrent methylxanthine therapy. No infant had clinically significant changes at the end of the study.
CONCLUSION: The initial changes in blood pressure may represent side effects of topical mydriatics but the later changes following the physical examination may be an additional response to the stress of ROP screening.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695564      PMCID: PMC505494          DOI: 10.1136/bjo.80.5.425

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

1.  The oculocardiac reflex.

Authors:  K M Dewar
Journal:  Proc R Soc Med       Date:  1976-05

2.  Consequences of retinopathy of prematurity examinations. Case report.

Authors:  J H Bates; R A Burnstine
Journal:  Arch Ophthalmol       Date:  1987-05

3.  Systemic cyclopentolate (Cyclogyl) toxicity in the newborn infant.

Authors:  C R Bauer; M C Trottier; L Stern
Journal:  J Pediatr       Date:  1973-03       Impact factor: 4.406

4.  Reduction in mydriatic drop size in premature infants.

Authors:  S Wheatcroft; A Sharma; J McAllister
Journal:  Br J Ophthalmol       Date:  1993-06       Impact factor: 4.638

5.  A comparison of mydriatic eyedrops in low-weight infants.

Authors:  S Isenberg; S Everett; E Parelhoff
Journal:  Ophthalmology       Date:  1984-03       Impact factor: 12.079

6.  Effects of cyclopentolate eyedrops on gastric secretory function in pre-term infants.

Authors:  S J Isenberg; C Abrams; P E Hyman
Journal:  Ophthalmology       Date:  1985-05       Impact factor: 12.079

7.  The oculocardiac reflex during ophthalmoscopy in premature infants.

Authors:  W N Clarke; E Hodges; L P Noel; D Roberts; M Coneys
Journal:  Am J Ophthalmol       Date:  1985-06-15       Impact factor: 5.258

8.  How safe are ocular drugs in pediatrics?

Authors:  E A Palmer
Journal:  Ophthalmology       Date:  1986-08       Impact factor: 12.079

9.  Increased blood pressure following pupillary dilation with 2.5% phenylephrine hydrochloride in preterm infants.

Authors:  B J Lees; L A Cabal
Journal:  Pediatrics       Date:  1981-08       Impact factor: 7.124

10.  Reduction of phenylephrine drop size in infants achieves equal dilation with decreased systemic absorption.

Authors:  M G Lynch; R H Brown; S M Goode; R D Schoenwald; D S Chien
Journal:  Arch Ophthalmol       Date:  1987-10
View more
  33 in total

1.  The optimum time to employ telephotoscreening to detect retinopathy of prematurity.

Authors:  K G Yen; D Hess; B Burke; R A Johnson; W J Feuer; J T Flynn
Journal:  Trans Am Ophthalmol Soc       Date:  2000

2.  Do we screen very premature babies too early for retinopathy of prematurity?

Authors:  G Kontos; A Khan; B W Fleck
Journal:  Eye (Lond)       Date:  2016-01-22       Impact factor: 3.775

3.  Is there a role for high-frequency ultrasonography in clinical staging of retinopathy of prematurity?

Authors:  Danny H Kauffinann Jokl; Ronald H Silverman; Sheri L Nemerofiky; Steven A Kane; Michael F Chiang; Robert Lopez; Grace Lee
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2006 Jan-Feb       Impact factor: 1.402

4.  Alternative methods for the screening of retinopathy of prematurity: binocular indirect ophthalmoscopy vs wide-field digital retinal imaging.

Authors:  M A Sekeroglu; E Hekimoglu; H T Sekeroglu; U Arslan
Journal:  Eye (Lond)       Date:  2013-06-14       Impact factor: 3.775

5.  Plus disease in retinopathy of prematurity: an analysis of diagnostic performance.

Authors:  Michael F Chiang; Rony Gelman; Lei Jiang; M Elena Martinez-Perez; Yunling E Du; John T Flynn
Journal:  Trans Am Ophthalmol Soc       Date:  2007

6.  Retinopathy of prematurity screening, stress related responses, the role of nesting.

Authors:  M Slevin; J F Murphy; L Daly; M O'Keefe
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

7.  Development and Evaluation of Reference Standards for Image-based Telemedicine Diagnosis and Clinical Research Studies in Ophthalmology.

Authors:  Michael C Ryan; Susan Ostmo; Karyn Jonas; Audina Berrocal; Kimberly Drenser; Jason Horowitz; Thomas C Lee; Charles Simmons; Maria-Ana Martinez-Castellanos; R V Paul Chan; Michael F Chiang
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

8.  Evaluation of retinopathy of prematurity screening in reverse Kangaroo Mother Care: a pilot study.

Authors:  T R Padhi; D Sareen; L Pradhan; S Jalali; S Sutar; T Das; R R Modi; U C Behera
Journal:  Eye (Lond)       Date:  2015-01-23       Impact factor: 3.775

9.  Can we reduce the burden of the current UK guidelines for retinopathy of prematurity screening?

Authors:  G G W Adams; C Williams; N Modi; W Xing; C Bunce; A Dahlmann-Noor
Journal:  Eye (Lond)       Date:  2017-08-11       Impact factor: 3.775

10.  Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): 18-month experience with telemedicine screening.

Authors:  Ruwan A Silva; Yohko Murakami; Atul Jain; Jarel Gandhi; Eleonora M Lad; Darius M Moshfeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.